Viyash Scientific Purchased Italian Pet-Care Firm
The acquisition of BioForLife Italia marks an expansion into European pet-care markets for the India-based group.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Do you believe domestic companies expanding internationally provides a net benefit to your country?
Viyash Scientific has acquired a 100% shareholding in Milan-based pet-care company BioForLife Italia for approximately ₹188 crore. The deal, completed via a step-down subsidiary, received necessary foreign direct investment and regulatory approvals in Italy.
Why it matters
This transaction signals a cross-border push to consolidate assets in the niche pet-care sector, allowing the acquiring group to leverage regional expertise and established distribution footprints.
Viyash Scientific acquired 100% of BioForLife Italia for ₹188 crore. The deal was finalized following rigorous legal, financial, and tax due diligence performed by BDO Italy.
The players
Viyash Scientific
An India-based firm focusing on scientific investments and corporate acquisitions.
BioForLife Italia
A Milan-based company specializing in the pet-care product market.
DSK Legal
A law firm providing structuring and negotiation services for complex cross-border transactions.
Alivira Animal Health Limited
An Ireland-based entity acting as the step-down subsidiary for the acquisition.
BDO Italy
A professional services network providing legal, financial, and tax due diligence for business acquisitions.
The details
The deal was structured and negotiated by DSK Legal, which handled the share purchase agreement and in-person discussions in Milan. Alivira Animal Health Limited, acting as a step-down subsidiary, facilitated the ownership transfer. The acquisition required specific compliance with Italian foreign direct investment and Golden Power regulations to proceed.
Timeline
October 1, 2026: The acquisition transaction was completed.
Market Landscape
The deal reflects an industry-wide trend where international firms must navigate the Italian Golden Power Regulations to enter European markets. This acquisition underscores how foreign direct investment hurdles are becoming a standard step in global M&A strategy.
Operators in the pet-care space should monitor how this consolidation affects supply chain integration and product pricing. Management should ensure that all cross-border deals include thorough regulatory mapping regarding local FDI and golden share protections.
The takeaway
This acquisition highlights the complexity of managing FDI compliance when entering foreign pet-care markets. For future growth, owners should prioritize a comprehensive due diligence team capable of navigating both the target's regulatory landscape and cross-border legal structures.
Further reading
For broader trends in medical and health-related industry consolidations, review our coverage on Healthcare.
Source note: This article includes information reported by Bar and Bench - Indian Legal news.
Live Poll
Do you believe domestic companies expanding internationally provides a net benefit to your country?
